secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001104659-24-083543
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q2 2024 revenue up 24% to $11.8M; net loss widens to $14.0M; updates FY guidance
--------------------------------------------------------------------------------

- Q2 2024 revenue $11.8M (+24% YoY); U.S. HF revenue $10.5M (+27% YoY); net loss $14.0M ($0.65/share) vs $11.6M ($0.56) in Q2 2023.
- Active implanting centers in U.S. reach 189, up 35% YoY; sales territories expanded to 42 from 39 in Q1.
- Cash and equivalents $70.4M; net cash used in operating/investing $10.2M in Q2, down from $11.8M in Q1.
- Hired Robert John as CRO, Dr. Philip Adamson as CMO, and other execs to strengthen commercial efforts.
- FY 2024 guidance: revenue $50-53M; gross margin 83-85%; operating expenses $95-98M (narrowed from $92-98M); Q3 revenue $12.7-13.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924083543/0001104659-24-083543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924083543/tm2420331d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-083543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer